| Literature DB >> 29867052 |
Abstract
MicroRNA (miRNA) transfection is known to degrade target mRNAs and to decrease mRNA expression. In contrast to the notion that most of the gene expression alterations caused by miRNA transfection involve downregulation, they often involve both up- and downregulation; this phenomenon is thought to be, at least partially, mediated by sequence-nonspecific off-target effects. In this study, I used tensor decomposition-based unsupervised feature extraction to identify genes whose expression is likely to be altered by miRNA transfection. These gene sets turned out to largely overlap with one another regardless of the type of miRNA or cell lines used in the experiments. These gene sets also overlap with the gene set associated with altered expression induced by a Dicer knockout. This result suggests that the off-target effect is at least as important as the canonical function of miRNAs that suppress translation. The off-target effect is also suggested to consist of competition for the protein machinery between transfected miRNAs and miRNAs in the cell. Because the identified genes are enriched in various biological terms, these genes are likely to play critical roles in diverse biological processes.Entities:
Keywords: miRNA transfection; sequence-nonspecific off-target regulation; tensor decomposition
Year: 2018 PMID: 29867052 PMCID: PMC6025034 DOI: 10.3390/cells7060054
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1The results on the artificial data: (A) averaged across 100 independent trials. The horizontal red dashed line is (B) averaged across 100 independent trials. The horizontal red dashed line is (C) A histogram of computed from . A vertical red segment represents the bin with the smallest P-values.
Eleven experiments conducted for this analysis. More detailed information is available in the text.
| Exp. | GEO ID | Cell Lines (Cancer) | miRNA | Misc |
|---|---|---|---|---|
| 1 | GSE26996 | BT549 (breast cancer) | miR-200a/b/c | |
| 2 | GSE27431 | HEY (ovarian cancer) | miR-7/128 | mas5 |
| 3 | GSE27431 | HEY (ovarian cancer) | miR-7/128 | plier |
| 4 | GSE8501 | Hela (cervical cancer) | miR-7/9/122a/128a/132/133a/142/148b/181a | |
| 5 | GSE41539 | CD1 mice | cel-miR-67,hsa-miR-590-3p,hsa-miR-199a-3p | |
| 6 | GSE93290 | multiple | miR-10a-5p,150-3p/5p,148a-3p/5p,499a-5p,455-3p | |
| 7 | GSE66498 | multiple | miR-205/29a/144-3p/5p,210,23b,221/222/223 | |
| 8 | GSE17759 | EOC 13.31 microglia cells | miR-146a/b | (KO/OE) |
| 9 | GSE37729 | HeLa | miR-107/181b | (KO/OE) |
| 10 | GSE37729 | HEK-293 | miR-107/181b | (KO/OE) |
| 11 | GSE37729 | SH-SY5Y | 181b | (KO/OE) |
OE: overexpression.
Fisher’s exact tests for coincidence among 11 miRNA transfection experiments. Upper triangle: P-value; lower triangle: odds ratio.
| Exp. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # | 232 | 711 | 747 | 441 | 123 | 292 | 246 | 873 | 113 | 104 | 120 | |
| 1 | 232 |
|
|
|
|
|
|
|
|
|
| |
| 2 | 711 | 7.68 | 0.00 |
|
|
|
|
|
|
|
| |
| 3 | 747 | 8.30 | 345.52 |
|
|
|
|
|
|
|
| |
| 4 | 441 | 18.23 | 5.19 | 5.34 |
|
|
|
|
|
|
| |
| 5 | 123 | 53.86 | 9.04 | 7.27 | 17.48 |
|
|
|
|
|
| |
| 6 | 292 | 61.50 | 8.15 | 5.52 | 17.71 | 204.39 |
|
|
|
|
| |
| 7 | 246 | 20.27 | 5.35 | 4.67 | 12.39 | 20.11 | 22.03 |
|
|
|
| |
| 8 | 873 | 18.61 | 7.22 | 6.51 | 8.29 | 15.61 | 18.53 | 20.73 |
|
|
| |
| 9 | 113 | 39.34 | 9.87 | 8.77 | 25.98 | 32.44 | 34.90 | 21.94 | 16.02 |
|
| |
| 10 | 104 | 40.29 | 8.22 | 8.27 | 26.64 | 23.34 | 20.86 | 21.56 | 15.18 | 517.87 |
| |
| 11 | 120 | 10.15 | 3.19 | 4.43 | 9.19 | 11.55 | 8.11 | 8.28 | 4.92 | 19.57 | 18.70 | |
#: the number of genes selected for each of 11 experiments via TD- or PCA-based unsupervised FE.
In each of 11 experiments, 20 top-ranked significant TFs whose sets of target genes significantly overlap with the set of genes selected for each experiment were identified. Then, EKLF, MYC, NELFA, and E2F1 turned out to be among the 20 top-ranked significant TFs for all 11 experiments.
| EKLF | MYC | NELFA | E2F1 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Exp. | #1 | #2 | OL | adj. | OL | adj. | OL | adj. | OL | adj. |
| 1 | 232 | 30 | 40/1239 |
| 53/1458 |
| 59/2000 |
| 61/1529 |
|
| 2 | 711 | 77 | 94/1239 |
| 106/1458 |
| 134/2000 |
| 100/1529 |
|
| 3 | 747 | 97 | 100/1239 |
| 98/1458 |
| 152/2000 |
| 108/1529 |
|
| 4 | 441 | 43 | 83/1239 |
| 99/1458 |
| 105/2000 |
| 85/1529 |
|
| 5 | 123 | 45 | 26/1239 |
| 25/1458 |
| 31/2000 |
| 28/1529 |
|
| 6 | 292 | 19 | 51/1239 |
| 65/1458 |
| 63/2000 |
| 69/1529 |
|
| 7 | 246 | 11 | 37/1239 |
| 48/1458 |
| 46/2000 |
| 64/1529 |
|
| 8 | 873 | 55 | 188/1239 |
| 189/1458 |
| 222/2000 |
| 157/1529 |
|
| 9 | 113 | 36 | 24/1239 |
| 30/1458 |
| 32/2000 |
| 40/1529 |
|
| 10 | 104 | 22 | 27/1239 |
| 25/1458 |
| 36/2000 |
| 35/1529 |
|
| 11 | 120 | 22 | 21/1239 |
| 27/1458 |
| 29/2000 |
| 25/1529 |
|
#1: the number of genes selected for each of 11 experiments via TD- or PCA-based unsupervised FE; #2: the number of TFs whose sets of target genes significantly (adjusted P-values ) overlap with the set of genes selected for each experiment; OL: overlaps, (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr as TF target genes).
In each of 11 experiments, 20 top-ranked significant KEGG pathways whose associated genes significantly match some genes selected for each experiment were identified. Thus, the following KEGG pathways are most frequently ranked within the top 20.
| Exp. | # | (i) | (ii) | (iii) | (iv) | (v) | (vi) | (vii) | (viii) | (ix) | (x) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (232) | 31/137 | 7/168 | 10/142 | 6/133 | 9/55 | 9/193 | 7/169 | 8/203 | ||
| [10] |
|
|
|
|
|
|
|
| |||
| 2 | (711) | 36/137 | 18/168 | 14/142 | 12/133 | 13/55 | 16/169 | 18/203 | |||
| [12] |
|
|
|
|
|
|
| ||||
| 3 | (747) | 23/137 | 15/168 | 14/55 | 18/169 | 19/203 | |||||
| [15] |
|
|
|
|
| ||||||
| 4 | (441) | 50/137 | 15/168 | 19/142 | 18/133 | 6/55 | 19/193 | 7/78 | 12/151 | 9/169 | |
| [10] |
|
|
|
|
|
|
|
|
| ||
| 5 | (123) | 9/137 | 8/78 | 6/169 | 8/203 | ||||||
| [23] |
|
|
|
| |||||||
| 6 | (292) | 45/137 | 20/168 | 19/142 | 18/133 | 4/55 | 19/193 | 11/78 | 12/151 | ||
| [14] |
|
|
|
|
|
|
|
| |||
| 7 | (246) | 40/137 | 9/168 | 10/142 | 9/133 | 11/193 | 4/78 | 7/151 | 6/203 | ||
| [6] |
|
|
|
|
|
|
|
| |||
| 8 | (873) | 75/137 | 30/168 | 32/142 | 32/133 | 36/193 | 14/78 | 24/151 | 25/169 | ||
| [24] |
|
|
|
|
|
|
|
| |||
| 9 | (113) | 18/137 | 11/168 | 12/142 | 10/133 | 6/55 | 12/193 | 4/78 | 11/151 | ||
| [20] |
|
|
|
|
|
|
|
| |||
| 10 | (104) | 11/137 | 8/168 | 9/142 | 8/133 | 5/55 | 10/193 | 8/151 | |||
| [20] |
|
|
|
|
|
|
| ||||
| 11 | (120) | 6/137 | 4/142 | 5/55 | 5/203 | ||||||
| [3] |
|
|
|
|
(i) Ribosome: hsa03010; (ii) Alzheimer’s disease: hsa05010; (iii) Parkinson’s disease: hsa05012; (iv) Oxidative phosphorylation: hsa00190; (v) Pathogenic Escherichia coli infection:hsa05130; (vi) Huntington’s disease: hsa05016; (vii) Cardiac muscle contraction: hsa04260; (viii) Nonalcoholic fatty liver disease (NAFLD): hsa04932; (ix) Protein processing in endoplasmic reticulum: hsa04141; and (x) Proteoglycans in cancer: hsa05205. (numbers): gene; [numbers]: KEGG pathways. Upper rows in each exp: (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category). Lower rows in each exp: adjusted P-values provided by Enrichr.
In each of 11 experiments, 20 top-ranked significant treatments with compounds whose downregulated genes significantly coincide with some genes selected for each experiment were identified. Thus, treatments with the following compounds are most frequently ranked within top 20.
| Exp. | # | (i) | (ii) | (iii) | (iv) | (v) | (vi) | (vii) | (viii) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (232) | OL | 10/85 | 16/154 | ||||||
| [129] | adj |
|
| |||||||
| 2 | (711) | OL | ||||||||
| [329] | adj | |||||||||
| 3 | (747) | OL | ||||||||
| [417] | adj | |||||||||
| 4 | (441) | OL | 16/85 | 14/105 | 15/109 | 16/144 | ||||
| [67] | adj |
|
|
|
| |||||
| 5 | (123) | OL | 17/141 | 12/154 | ||||||
| [219] | adj |
|
| |||||||
| 6 | (292) | OL | 13/105 | 19/137 | ||||||
| [132] | adj |
|
| |||||||
| 7 | (246) | OL | 9/85 | 12/154 | ||||||
| [61] | adj |
|
| |||||||
| 8 | (873) | OL | 30/85 | 46/141 | 35/162 | |||||
| [255] | adj |
|
|
| ||||||
| 9 | (119) | OL | 9/85 | 11/141 | 8/109 | 8/144 | 8/162 | 12/137 | ||
| [74] |
|
|
|
|
|
| ||||
| 10 | (104) | OL | 9/85 | 9/105 | 9/109 | 10/144 | 12/137 | |||
| [155] | adj |
|
|
|
|
| ||||
| 11 | (120) | OL | 10/141 | 9/162 | ||||||
| [127] | adj |
|
|
(i) LJP005_BT20_24H-GSK-1059615-3.33; (ii) LJP005_HS578T_24H-LDN-193189-10; (iii) LJP005_MCF10A_24H-GSK-1059615-10; (iv) LJP006_BT20_24H-WYE-125132-10; (v) LJP006_HS578T_24H-afatinib-10; (vi) LJP006_MCF10A_24H-PI-103-10; (vii) LJP007_HT29_24H-PD-0325901-0.12; and (viii) LJP009_HEPG2_24H-chelerythrine_chloride-10. #: (numbers): genes; [numbers]: compounds. Upper rows in each exp: OL, overlaps, (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category). Lower rows in each exp: adjusted P-values provided by Enrichr.
In each of the 11 experiments, 20 top-ranked significant treatments with compounds whose sets of upregulated genes significantly overlap with the set of genes selected for each experiment were identified. Therefore, treatment with the following compounds is most frequently ranked within the top 20.
| Exp. | # | (i) | (ii) | (iii) |
|---|---|---|---|---|
| 1 | (232) | 16/166 | ||
| [191] |
| |||
| 2 | (711) | 23/125 | 30/163 | |
| [450] |
|
| ||
| 3 | (747) | 34/163 | ||
| [559] |
| |||
| 4 | (441) | 15/125 | ||
| [85] |
| |||
| 5 | (123) | |||
| [116] | ||||
| 6 | (292) | 18/163 | ||
| [190] |
| |||
| 7 | (246) | |||
| [145] | ||||
| 8 | (873) | 22/125 | 31/166 | |
| [69] |
|
| ||
| 9 | (119) | 8/166 | ||
| [0] |
| |||
| 10 | (104) | |||
| [0] | ||||
| 11 | (120) | |||
| [33] |
(i) LJP005_A375_24H-GDC-0980-0.37; (ii) LJP005_HEPG2_24H-PLX-4720-10; and (iii) LJP007_MCF7_24H-dinaciclib-0.12 #: (numbers): genes; [numbers]: compounds. Upper rows in each exp: OL, overlaps (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category). Lower rows in each exp: adjusted P-values provided by Enrichr.
In each of the 11 experiments, 20 top-ranked significant tissues whose set of upregulated genes significantly overlapped with the set of genes selected for each experiment were identified.
| Exp. | # | (i) | (ii) | (iii) | (iv) | (v) | (vi) | (vii) | (viii) | (ix) | (x) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (232) | 68/1509 | 51/1066 | 65/1384 | 74/1773 | 77/1764 | 69/1770 | 53/1174 | 68/1710 | ||
| [216] |
|
|
|
|
|
|
|
| |||
| 2 | (711) | 78/625 | |||||||||
| [470] |
| ||||||||||
| 3 | (747) | 72/625 | |||||||||
| [441] |
| ||||||||||
| 4 | (441) | 80/1509 | 61/1066 | 82/1384 | 87/1764 | 54/625 | 54/525 | ||||
| [151] |
|
|
|
|
|
| |||||
| 5 | (123) | 31/1509 | 29/1066 | 32/1384 | 33/1773 | 34/1770 | 26/1174 | 33/1710 | |||
| [150] |
|
|
|
|
|
|
| ||||
| 6 | (292) | 80/1509 | 66/1066 | 70/1384 | 80/1773 | 85/1764 | 46/625 | 78/1770 | 50/525 | 63/1174 | 76/1710 |
| [196] |
|
|
|
|
|
|
|
|
|
| |
| 7 | (246) | 64/1509 | 53/1066 | 57/1384 | 68/1773 | 68/1764 | 34/625 | 63/1770 | 35/525 | 52/1174 | 63/1710 |
| [135] |
|
|
|
|
|
|
|
|
|
| |
| 8 | (873) | 164/1509 | 131/1066 | 156/1384 | 155/1773 | 168/1764 | 161/1770 | 128/1174 | 157/1710 | ||
| [178] |
|
|
|
|
|
|
|
| |||
| 9 | (119) | 39/1509 | 28/1066 | 40/1384 | 38/1773 | 37/1764 | 24/625 | 25/525 | |||
| [225] |
|
|
|
|
|
|
| ||||
| 10 | (104) | 29/1509 | 22/1066 | 30/1384 | 31/1773 | 29/1764 | 28/1770 | 15/525 | 23/1174 | 27/1710 | |
| [156] |
|
|
|
|
|
|
|
|
| ||
| 11 | (120) | 13/625 | 12/525 | ||||||||
| [5] |
|
|
(i) GTEX-QDT8-0011-R10A-SM-32PKG_brain_female_30-39_years; (ii) GTEX-QMR6-1426-SM-32PLA_brain_male_50-59_years; (iii) GTEX-TSE9-3026-SM-3DB76_brain_female_60-69_years; (iv) GTEX-PVOW-0011-R3A-SM-32PKX_brain_male_40-49_years; (v) GTEX-PVOW-2526-SM-2XCF7_brain_male_40-49_years; (vi) GTEX-XAJ8-1326-SM-47JYT_testis_male_40-49_years; (vii) GTEX-N7MS-0011-R3a-SM-33HC6_brain_male_60-69_years; (viii) GTEX-OHPM-2126-SM-3LK75_testis_male_50-59_years; (ix) GTEX-PVOW-0011-R5A-SM-32PL7_brain_male_40-49_years; and (x) GTEX-PVOW-2626-SM-32PL8_brain_male_40-49_years. (numbers): gene; [numbers]: tissues. P-values are the ones adjusted by Enrichr.
In each of the 11 experiments, 20 top-ranked significant tissues whose set of downregulated genes significantly overlapped with the set of genes selected for each experiment were identified.
| Exp. | # | (i) | (ii) | (iii) | (iv) | (v) | (vi) |
|---|---|---|---|---|---|---|---|
| 1 | (232) | 57/1709 | 54/1488 | 53/1027 | 53/1121 | 55/1599 | 52/1103 |
| [201] |
|
|
|
|
|
| |
| 2 | (711) | 166/1709 | 133/1121 | 175/1599 | |||
| [414] |
|
|
| ||||
| 3 | (747) | 174/1709 | 165/1599 | ||||
| [365] |
|
| |||||
| 4 | (441) | 98/1709 | 89/1488 | 73/1027 | 98/1599 | 70/1103 | |
| [219] |
|
|
|
|
| ||
| 5 | (123) | 35/1027 | 35/1121 | 37/1103 | |||
| [486] |
|
|
| ||||
| 6 | (292) | 69/1488 | 60/1027 | 53/1121 | 61/1103 | ||
| [171] |
|
|
|
| |||
| 7 | (246) | 55/1488 | 57/1027 | 49/1121 | 53/1599 | 51/1103 | |
| [113] |
|
|
|
|
| ||
| 8 | (873) | 188/1709 | 137/1027 | 136/1121 | 182/1599 | 138/1103 | |
| [185] |
|
|
|
|
| ||
| 9 | (119) | 31/1709 | 36/1488 | ||||
| [224] |
|
| |||||
| 10 | (104) | 31/1709 | 33/1488 | ||||
| [156] |
|
| |||||
| 11 | (120) | ||||||
| [20] |
(i) GTEX-Q2AH-0008-SM-48U2J_skin_male_40-49_years; (ii) GTEX-O5YT-0126-SM-48TBW_skin_male_20-29_years; (iii) GTEX-P4PQ-0008-SM-48TDX_skin_male_60-69_years; (iv) GTEX-R55D-0008-SM-48FEV_skin_male_50-59_years; (v) GTEX-R55E-0008-SM-48FCG_skin_male_20-29_years; and (vi) GTEX-RU72-0008-SM-46MV8_skin_female_50-59_years. (numbers): gene; [numbers]: tissues. Upper rows in each exp: OL, overlaps (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category). Lower rows in each exp: adjusted P-values provided by Enrichr.
In each of the 11 experiments, 20 top-ranked significant terms in the Embryonic Stem Cell Atlas from Pluripotency Evidence (ESCAPE) whose set of associated genes significantly overlapped with the set of genes selected for each experiment were identified.
| Exp. | # | (i) | (ii) | (iii) | (iv) | (v) | (vi) | (vii) | (viii) | (ix) | (x) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (232) | 53/1458 | 90/2469 | 55/1789 | 56/1200 | 24/705 | 38/1700 | 40/1502 | 15/315 | 17/186 | 66/3249 |
| [15] |
|
|
|
|
|
|
|
|
|
| |
| 2 | (711) | 106/1458 | 184/2469 | 96/1789 | 90/1200 | 33/315 | 182/3249 | ||||
| [22] |
|
|
|
|
|
| |||||
| 3 | (747) | 98/1458 | 199/2469 | 106/1789 | 93/1200 | 55/705 | 32/315 | 19/186 | 184/3249 | ||
| [28] |
|
|
|
|
|
|
|
| |||
| 4 | (441) | 99/1458 | 153/2469 | 109/1789 | 95/1200 | 51/705 | 64/1700 | 60/1502 | 23/186 | 145/3249 | |
| [18] |
|
|
|
|
|
|
|
|
| ||
| 5 | (123) | 25/1458 | 46/2469 | 26/1789 | 19/315 | ||||||
| [32] |
|
|
|
| |||||||
| 6 | (292) | 65/1458 | 108/2469 | 54/1789 | 59/1200 | 24/705 | 47/1700 | 37/1502 | 13/315 | 19/186 | 68/3249 |
| [8] |
|
|
|
|
|
|
|
|
|
| |
| 7 | (246) | 48/1458 | 78/2469 | 43/1789 | 49/1200 | 17/705 | 31/1700 | 33/1502 | 13/315 | 15/186 | |
| [6] |
|
|
|
|
|
|
|
|
| ||
| 8 | (873) | 189/1458 | 303/2469 | 184/1789 | 159/1200 | 89/705 | 130/1700 | 116/1502 | 38/315 | 38/186 | 247/3249 |
| [28] |
|
|
|
|
|
|
|
|
|
| |
| 9 | (119) | 30/1458 | 54/2469 | 37/1789 | 28/1200 | 16/705 | 23/1700 | 28/1502 | 9/186 | 32/3249 | |
| [14] |
|
|
|
|
|
|
|
|
| ||
| 10 | (104) | 25/1458 | 56/2469 | 33/1789 | 21/1200 | 13/705 | 23/1700 | 19/1502 | 10/186 | ||
| [11] |
|
|
|
|
|
|
|
| |||
| 11 | (120) | 27/1458 | 44/2469 | 17/1200 | 13/705 | 23/1700 | 25/1502 | 7/315 | |||
| [14] |
|
|
|
|
|
|
|
(i) CHiP_MYC-19079543; (ii) mESC_H3K36me3_18692474; (iii) CHiP_DMAP1-20946988; (iv) CHiP_MYC-18555785; (v) CHiP_TIP60-20946988; (vi) CHiP_KLF4-18358816; (vii) CHiP_KLF4-19030024; (viii) SUZ12-17339329_UP; (ix) ZFP281-21915945_DOWN; and (x) CHiP_ZFX-18555785. (numbers): gene; [numbers]: TF binding, histone modification and a gene KO or overexpression. Upper rows in each exp: OL, overlaps (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category). Lower rows in each exp: adjusted P-values provided by Enrichr.
PPI enrichment by the STRING server. Column “genes” shows numbers of genes recognized by the STRING server.
| Exp. | Genes | Edges | ||
|---|---|---|---|---|
|
|
| |||
| 1 | 195 | 1638 | 591 | 0 |
| 2 | 623 | 4271 | 2577 | 0 |
| 3 | 658 | 4506 | 2920 | 0 |
| 4 | 392 | 3418 | 1273 | 0 |
| 5 | 118 | 539 | 197 | 0 |
| 6 | 276 | 2048 | 569 | 0 |
| 7 | 182 | 1167 | 303 | 0 |
| 8 | 640 | 10176 | 4342 | 0 |
| 9 | 112 | 464 | 165 | 0 |
| 10 | 103 | 323 | 127 | 0 |
| 11 | 118 | 143 | 104 |
|
In each of the 11 experiments, 20 top-ranked significant terms in GeneSigDB whose set of associated genes significantly overlapped with the set of genes selected for each experiment were identified.
| (i) | (ii) | (iii) | (iv) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Exp. | #1 | #2 | OL | adj. | OL | adj. | OL | adj. | OL | adj. |
| 1 | 232 | 154 | 97/1548 |
| 36/663 |
| 77/2585 |
| 36/238 |
|
| 2 | 711 | 194 | 152/1548 |
| 72/663 |
| 222/2585 |
| 44/238 |
|
| 3 | 747 | 285 | 149/1548 |
| 87/663 |
| 222/2585 |
| 30/238 |
|
| 4 | 441 | 106 | 146/1548 |
| 62/663 |
| 145/2585 |
| 46/238 |
|
| 5 | 123 | 183 | 44/1548 |
| 13/663 |
| 37/2585 |
| 24/238 |
|
| 6 | 292 | 106 | 103/1548 |
| 36/663 |
| 94/2585 |
| 39/238 |
|
| 7 | 246 | 95 | 81/1548 |
| 30/663 |
| 66/2585 |
| 30/238 |
|
| 8 | 873 | 269 | 256/1548 |
| 100/663 |
| 229/2585 |
| 86/238 |
|
| 9 | 119 | 93 | 60/1548 |
| 30/663 |
| 48/2585 |
| 22/238 |
|
| 10 | 104 | 77 | 52/1548 |
| 25/663 |
| 45/2585 |
| 15/238 |
|
| 11 | 120 | 68 | 36/1548 |
| 17/663 |
| 40/2585 |
| 13/238 |
|
(i) A multiclass predictor based on a probabilistic model, i.e., application to gene expression profiling-based diagnosis of thyroid tumors; (ii) A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis; (iii) A comparison of the gene expression profile of undifferentiated human embryonic stem cell lines and differentiating embryoid bodies; and (iv) A gene expression profile of rat left ventricles reveals persisting changes after a chronic mild-exercise protocol: implications for cardioprotection. #1: genes; #2: terms. OL: overlaps (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category).
Figure 2A schematic diagram that summarizes the obtained results.
GEO DICER KO: The number of experiments among the 16 experiments included in Enrichr whose set of listed genes significantly overlapped with the set of genes identified in each of the 11 experiments. IP: Fisher’s exact test for the overlap between the set of genes that bind to Dicer in immunoprecipitation (IP) experiments and the set of genes selected in each of the 11 experiments.
|
|
|
|
|
|
|
| |
| GEO DICER KO | up | 12/16 | 12/16 | 12/16 | 12/16 | 14/16 | 11/16 |
| down | 13/16 | 12/16 | 12/16 | 13/16 | 14/16 | 10/16 | |
| IP |
|
|
|
|
|
| |
| odds | 47.4 | 20.6 | 15.9 | 38.7 | 64.2 | 41.2 | |
|
|
|
|
|
|
| ||
| GEO DICER KO | up | 12/16 | 14/16 | 12/16 | 13/16 | 12/16 | |
| down | 12/16 | 12/16 | 14/16 | 14/16 | 10/16 | ||
| IP |
|
|
|
|
| ||
| odds | 37.0 | 41.4 | 42.6 | 39.6 | 27.3 |
Figure 3A boxplot of the number of miRNAs that target individual genes as a function of the number of experiments that select individual genes within 11 experiments (most frequently selected genes were selected in nine experiments): (Left) raw numbers (Pearson’s correlation coefficient = 0.13, ); and (Right) ranks of numbers (Spearman’s correlation coefficient = 0.29, )
Figure 4(A) The scatter plot of for GSE26996; 379 red dots are selected probes; and (B) a semilogarithmic plot of the histogram of under the null hypothesis that obeys a normal distribution. A sharp peak is observed in the red bin with the largest , which includes all the probes selected in (A).